Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions
CNS Specialist ‘Now Able To Bring New Products To The Greek Market’
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
You may also be interested in...
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.
Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.